Catalog No.: PC-61475Not For Human Use, Lab Use Only.
Ladarixin sodium (DF-2156) is an allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
Ladarixin sodium (DF-2156) is an allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
Ladarixin prevents PMN infiltration and tissue damage in several models of IR injury in vivo.
Ladarixin abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts.
Ladarixin also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice.
Physicochemical Properties
M.Wt
397.315
Formula
C11H11F3NNaO6S2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
100 mM in DMSO
Chemical Name/SMILES
4-((2R)-1-Oxo-1-(methanesulfonamido)propan-2-yl)phenyl trifluoromethanesulfonate sodium salt
References
1. Garau A, et al. Eur Cytokine Netw. 2006 Mar;17(1):35-41.
2. Citro A, et al. Diabetes. 2015 Apr;64(4):1329-40.
3. Kemp DM, et al. Oncotarget. 2017 Feb 28;8(9):14428-14442.
4. Bertini R, et al. Br J Pharmacol. 2012 Jan;165(2):436-54.
